学校放假了，那么现在你做什么来吸引你的孩子呢?6月29日，一些家长带着他们的家人来到宾夕法尼亚州的哈里斯堡，参加2016年宾夕法尼亚州宣传和获取日。一些年轻人已经是专业人士了，他们参加了之前的宣传活动和我们的Advocacy Summit in Washington, DC. For others it was a first time experience.
Continue readingYoung Advocates in Pennsylvania Speak Out
Tag Archives: Biosimilars
Arthritis Foundation Collaborates with Providers at the State Level to Advocate for the Arthritis Community
我们的宣传团队在州一级非常活跃，带头确保关节炎患者能够获得关键的药物。我们的志愿倡导者做了一个significant impactand help achieve tangible results by sharing their stories and asking elected officials to support legislation that is important to them and their families. But beyond fighting for key legislative changes and being vocal in raising awareness and sharing stories that help put faces with arthritis, we also make strides for the arthritis community when we link the voices of patient with the provider community – as we have done recently and successfully in New York and Ohio.
Continue readingArthritis Foundation Collaborates with Providers at the State Level to Advocate for the Arthritis Community
Breaking Advocacy News in Missouri – Senate Bill 875 Regarding Biosimilars has Been Signed Into Law!
Kyleigh O’Brien is an 11-year-old withjuvenile arthritisand has testified in front of the Missouri legislature twice this year. Why does she do it?
She wants to be a voice for the estimated 300,000 children in the United States who live with arthritis. Kyleigh has advocated most recently for the passage of Missouri Senate Bill 875 (SB 875), which has now been signed into law by Governor Jay Nixon.
Continue readingBreaking Advocacy News in Missouri – Senate Bill 875 Regarding Biosimilars has Been Signed Into Law!
亚利桑那州关节炎倡导者取得生物仿制药的胜利!
With new, innovative arthritis medications coming to market, patients with arthritis may soon have access to potentially less expensive biosimilar medications (similar to biologics).
However, imagine that, without your knowledge, your pharmacy substituted the biologic medication prescribed by your doctor with a new interchangeable biosimilar. Residents of Arizona no longer have to worry because this week, Arizona Governor Doug Ducey signed House Bill 2310 (HB 2310) into law. HB 2310 allows pharmacists to substitute biologic medications with new, interchangeable and potentially less expensive biosimilar medications when they come to market. The bill also ensures patients and their physicians know when a substitution occurs, resulting in a complete and accurate patient medical record. And, if physicians do not want a substitution to occur, they can stipulate that the prescription be dispensed as written.
Continue reading亚利桑那州关节炎倡导者取得生物仿制药的胜利!
Advocates in Kentucky Get a Big Win for Biosimilar Substitution
Big news for our arthritis community in Kentucky! On April 13, 2016, Gov. Matt Bevin (R – KY) signed Senate Bill 134 into law. The law creates a pathway for the introduction and use of biosimilars into the mainstream marketplace. Biosimilar medications have the potential to provide safe and effective treatment to people with arthritis at a potentially lower cost than name-brand biologic medications.
The many letters, calls and visits made by Arthritis Foundation Advocates in Kentucky played a significant role in the passage of SB 134.
Continue readingAdvocates in Kentucky Get a Big Win for Biosimilar Substitution
Arthritis Foundation Advocates Achieve Legislative Victory in New Jersey – Biosimilars Become Available!
Today we celebrate a huge victory for the arthritis community in New Jersey! New Jersey’s Governor, Chris Christie, has signed into law Assembly Bill 2477, a bill that allows biosimilar medications to become available for people with arthritis and other chronic diseases.
AB-2477 creates a pathway for biosimilars to enter the market place, potential for the development of new and innovative medications, andimprovesaccess to additional treatment options for people currently relying on biologics.Unlike other generic drug alternatives, biosimilars are developed from proteins in living cells and are highly similar to biologic medications.
Arthritis Foundation Advocates Help Achieve 3 Big Victories in California!
Recently, the Arthritis Foundation lead the charge in the passage of three new laws in the state of California that will ensure patient care and continue to keep prescription costs low. The laws focused on issues dealing with Biosimilar Substitution, Step Therapy, and controlling out-of-pocket costs for residents of California.
With specific regard to the new legislation regulating the step therapy process, Krystin Herr, vice president of government affairs and advocacy in the pacific region for the Arthritis Foundation, stated, “Many patients with complex chronic conditions, such as rheumatoid arthritis, do not always fit a ‘one size fits all’ approach to medication. However, step therapy protocols do not reflect that.”
Continue readingArthritis Foundation Advocates Help Achieve 3 Big Victories in California!
A Big Win For Arthritis Foundation Advocates: FDA Proposal Would Require Unique Names for Biosimilars
Today, we celebrate our tremendous Advocates and a fantastic victory! The FDA has issued proposed guidance to require unique names for biosimilar products that have submitted applications to the FDA.
The Arthritis Foundation and our team of 125,000 advocates have advocated for distinguishable names to ensure patient safety is given the highest priority. Unlike generic medications, biosimilars are not necessarily exact copies of brand name biologics. The change will lessen confusion among prescribers, allow for transparency in notification and drug substitution, strengthen patient adverse reaction tracking and make data collection easier.
Advocates in Illinois Get a Big Win for Biosimilars
Thanks in large part to the many letters, calls and visits made by Arthritis Foundation Advocates in Illinois, on July 30, Gov. Bruce Rauner (R – IL) signed Senate Bill 455 into law.
该法律为生物仿制药的引进和使用进入主流市场开辟了一条途径。生物仿制药有可能以比名牌生物药物更低的成本为关节炎患者提供安全有效的治疗。
Biologics are carefully engineered, and they can never truly be duplicated. This means that even biosimilars deemed interchangeable are not generic replicas of original biologics. Nationwide, states are now enacting legislation to create a pathway for biosimilars because current laws on generic substitution do not have jurisdiction on biosimilars.
Continue readingAdvocates in Illinois Get a Big Win for Biosimilars